Reuters Publishes Akin Article on the Inflation Reduction Act and Its Impact on Patent Litigation

September 6, 2023

Reading Time : 1 min

Reuters has published “Navigating the Parallel Path of Patent Litigation Alongside the Inflation Reduction Act,” an article by Akin partners Michael P. Kahn and Craig B. Bleifer and counsel Caitlin E. Olwell. The lawyers hail from the firm’s market-leading intellectual property (IP) and health care & life sciences groups.

In the article, the authors discuss the impact of the Inflation Reduction Act (IRA) on patent litigation involving pharmaceuticals and biologics. The IRA complicated an already “complex interplay between patent law, court procedures and Food and Drug Administration (FDA)/regulatory regimes.”

The authors expect that the new IRA regulatory regime will be relevant to patent litigations concerning “selected” drug products and that practitioners should pay close attention in the coming months and consider employing a coordinated approach involving regulatory, patent litigation and business teams.

To read the complete article, click here.

Share This Insight

Previous Entries

IP Newsflash

February 24, 2026

The Southern District of Florida recently dismissed a complaint without prejudice because the allegations used a form of “shotgun pleading.” The court explained that a shotgun pleading includes those where every count incorporates every preceding paragraph into each cause of action, and that dismissal of such pleadings was required under Eleventh Circuit precedent.

...

Read More

IP Newsflash

February 20, 2026

The Federal Circuit recently addressed whether the PTO must conduct notice‑and‑comment rulemaking before issuing instructions that guide how the Board should exercise discretion at the institution stage of IPRs. The court held that no such rulemaking is required. Instructions to the Board regarding its use of the Director’s delegated discretionary authority not to institute review are merely general statements of policy exempt from notice-and-comment rulemaking.  

...

Read More

IP Newsflash

February 18, 2026

The District Court for the District of Delaware recently invalidated claims directed to a panoramic objective lens for lack of enablement, holding the claims impermissibly recited a single element in means‑plus‑function form. Under § 112, ¶ 6, “[a]n element in a claim for a combination may be expressed as a means or step for performing a specified function….” By its plain terms, the statute permits means‑plus‑function claiming only in the context of a “combination.” In other words, a claim may not consist solely of a single means‑plus‑function element. Claims drafted as a single means are invalid for lack of enablement as a matter of law.

...

Read More

IP Newsflash

February 13, 2026

In an ANDA litigation, the District of Delaware recently denied the defendants’ motion to compel the production of correspondence between the plaintiffs’ testifying expert and a third-party analyst who had performed experiments and provided data used by the testifying expert. The court found that the scope of material sought by the motion was overbroad and disproportionate to the needs of the case.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.